Since the adaptive Phase II I-SPY 2 study began in 2010, two of the three original compounds have graduated, and five more have been added. Compounds graduate or are dropped based on statistical modeling that predicts the likelihood of success in a Phase III trial in neoadjuvant breast cancer. The graduations actually happened in 2012 but were not publicly announced until December 2013 to preserve blinding. The status of the third original compound and the five additions have not been announced.